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Abstract
Interleukin-2 (IL-2) has been shown to promote tumor-specific T-cell proliferation and differentiation but systemic
administration of IL-2 results in significant toxicity. Therefore, a strategy that can specifically deliver IL-2 to the tumor
location may alleviate concerns of toxicity. Because NKG2D ligands have been shown to be highly expressed in many cancer
cells but not in healthy cells, we reason that a chimeric protein consisting of NKG2D linked to IL-2 will lead to the specific
targeting of IL-2 to the tumor location. Therefore, we created chimeric proteins consisting of NKG2D linked to Gaussia
luciferase (GLuc; a marker protein) or IL-2 to form NKG2D-Fc-GLuc and NKG2D-Fc-IL2, respectively. We demonstrated that
NKG2D linked to GLuc was able to deliver GLuc to the tumor location in vivo. Furthermore, we showed that TC-1 tumor-
bearing mice intramuscularly injected with DNA encoding NKG2D-Fc-IL2, followed by electroporation, exhibited an
increased number of luciferase-expressing E7-specific CD8+ T cells at the tumor location. More importantly, treatment with
the DNA construct encoding NKG2D-Fc-IL2 significantly enhanced the therapeutic anti-tumor effects generated by
intradermal vaccination with therapeutic HPV DNA in tumor-bearing mice. Therefore, by linking NKG2D to IL2, we are able
to specifically deliver IL-2 to the tumor location, enhancing antigen-specific T-cell immune response and controlling tumor
growth. Our approach represents a platform technology to specifically deliver proteins of interest to tumor loci.
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Introduction
Conventional chemotherapy and radiotherapy treatments are
commonly plagued with toxic side effects since they are often not
developed with high specificity to cancer cells. That is, both
healthy and cancerous cells are affected, resulting in significant
side effects and toxicity. Therefore, there is an urgent need for
tumor-specific treatments that will be more effective than the
conventional therapies in specifically targeting the tumorigenic
cells, while not jeopardizing healthy organs and/or the well-being
of the patient [1]. In this regard, antigen-specific T cell
immunotherapy for cancer has emerged as a promising approach
for specifically targeting tumor cells but not normal cells.
One common approach for antigen-specific T cell immuno-
therapy is to use ex vivo expansion of antigen-specific T cells with
their subsequent transfer to the patient. Several approaches have
been used to improve the antigen specificity of T cells, such as in
vitro stimulation of the T cell by antigen-pulsed dendritic cells.
Alternatively T cells can be transduced with a chimeric antigen
receptor that can activate T cells through the T cell signaling
pathway while bestowing the T cell with tumor specificity (for
reviews, see [2,3,4]). Many of these approaches using adoptive
transfer of antigen-specific CD8+ T cells require the administra-
tion of IL-2.
Interleukin-2 (IL-2) is a cytokine from the cytokine-receptor c-
chain family with many functions including stimulating the
proliferation of T cells, inducing the production of NK cells,
inducing cytotoxic T lymphocyte generation, and facilitating the
proliferation and synthesis of immunoglobulins produced by B
cells [5]. IL-2 induces effects by binding to pre-formed high-
affinity heterotrimeric IL-2 receptors at the surface of activated
cells. Because of its functional versatility, IL-2 has previously
been used in experiments to augment the immune system [6]. It
has also been shown that activated T cells can be supported by
transgenic expression of IL-2 in vivo [7,8] and IL-2 has already
been approved for clinical use in patients with metastatic renal-
cell carcinoma and malignant melanoma [5]. However, when
administered systemically in high doses, tumor regression comes
with transient side effects ranging from general malaise, fever,
and nausea and vomiting to more severe hepatic dysfunction,
increased capillary permeability, and decreased systemic vascular
resistance [9,10]. Thus, a strategy that is able to specifically
deliver IL-2 to the tumor location will significantly reduce the
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side effects commonly associated with its systemic administration.
Identifying surface molecules that are specifically expressed in
tumor cells but not in normal cells will be useful for the specific
delivery of IL-2 to the tumor loci. For example, multiple NKG2D
ligands have been identified and are known to be upregulated in
transformed, infected, and/or stressed cells but not in substantial
amounts in healthy adult cells [11]. Cellular and genotoxic
stresses, like excessive proliferation, heat shock, or oxidative stress,
are just some of the factors that lead to the upregulation of
NKG2D ligands. Consequently, NKG2D ligands are highly
expressed in multiple tumors of different origins, though in
varying proportions [12]. Thus IL-2 can potentially be linked to
NKG2D for its specific delivery to the tumor loci.
For the current study, we have generated a chimeric molecule
linking murine IL-2 to the extracellular domain of murine
NKG2D with an IgG2a Fc region (to facilitate purification) to
form the chimeric NKG2D-Fc-IL2 protein. Here, we show that
NKG2D-Fc-IL2 was able to bindt om u r i n eN K G 2 Dl i g a n d -
expressing tumor cells. Furthermore, the IL-2 component of the
chimeric protein was capable of inducing proliferation of T cells
in vitro and at the tumor site in vivo.M o r ei m p o r t a n t l y ,T C - 1
tumor-bearing mice treated with a therapeutic HPV type 16
E7 DNA vaccine and then given the DNA construct encoding
the chimeric NKG2D-Fc-IL2 protein demonstrated reduced
tumor mass growth and prolonged survival. Thus the data
suggest the chimeric NKG2D-Fc-IL2 technology has potential
to be used to further enhance the therapeutic anti-tumor effect
generated by the therapeutic HPV DNA vaccine. Potential
translational and clinical applications of this approach will be
discussed.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations of the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All procedures were
performed with prior approval of the Johns Hopkins Animal Care
and Use Committee (protocol MO08M446).
Mice
Six- to eight-week-old female C57BL/6 mice were purchased
from the National Cancer Institute (Frederick, MD) and housed in
the Johns Hopkins Oncology Center Animal Facility located in
Cancer Research Building II (Johns Hopkins School of Medicine,
Baltimore, MD). All animal procedures were performed according
to approved protocols and in accordance with recommendations
for the proper use and care of laboratory animals.
Cells
TC-1 cells were produced in our laboratory and maintained as
previously described [13]. Ovarian surface epithelial carcinoma
(MOSEC) [14] cells were provided by Dr. Katherine Roby
(University of Kansas Medical Center). The generation of the
luciferase-expressing E7 (aa49-57)-specific T cell line has also been
previously described [15]. Baby hamster kidney (BHK)-21 cells
were obtained from ATCC (Rockville, MD). Cell lines were
cultured in vitro in RPMI 1640 supplemented with 10% fetal
bovine serum, 50 units/ml of penicillin/streptomycin, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 2 mM non-essential
amino acids, and grown at 37uC with 5% CO2.
Plasmid DNA Constructs and Preparation
pFuse-Fc (pFuse-mIgG2a-Fc2) was obtained from Invivogen
(San Diego, USA). To generate pFuse-NKG2D-Fc, the extracel-
lular domain of murine NKG2D was PCR amplified by primers
(aaaGAATTCGaaagagacgtttcagccagt and tttAGATCTcaccgcc-
cttttcatgcaga) with mouse NKG2D cDNA as the template DNA
(Open Biosystems, Lafayette CO), and then cloned into EcoRI
and Bgl II sites of pFuse-IgG2a (Invivogen). To clone pFuse-
NKG2D-Fc-GLuc, the GLuc gene was amplified by PCR using
primers (AAATCTAGAgaggccaagcccaccgagaac and aaaCTC-
GAGttagtcaccaccggccccctt) and cloned into the XbaI/XhoI sites
of pFuse-NKG2D. The same process was employed to construct
pFuse-Fc-GLuc using pFuse-Fc instead of pFuse-NKG2D. For
pFuse-NKG2D-FC-IL2, IL-2 was PCR amplified using primers
(aaatctagaGCACCCACTTCAAGCTCCACT and aaaCTC-
GAGttattgagggcttgttgaga) with a murine pcDNA3-IL2 construct
as a template [16], and then cloned into XbaI/XhoI sites of
pFuse-NKG2D-Fc. pFuse-Fc-IL2 was constructed using the PCR
product of IL-2 cloned into the XbaI/XhoI sites of pFuse-Fc.
Schematic diagram of the various chimeric genes encoded by the
DNA constructs is depicted in Figure S1.
Transfection and Protein Purification
For the production of the recombinant protein NKG2D-Fc-IL2
and control proteins IgG2a Fc (hereinafter ‘‘Con-Fc’’), Con-Fc-
GLuc, NKG2D-Fc, NKG2D-Fc-GLuc, Con-Fc-IL2, 16l0
7 BHK-
21 cells were transfected with 50mg of each plasmid in T-150 flasks
using Lipofectamin 2000 (Invitrogen Corp., Carlsbad, CA, USA).
After 3 days, the cell-cultured media was accumulated, filtered
with a 0.22mm syringe filter (Millipore, Billerica MA, USA) and
concentrated with Amicon Ultra-15 50kDa cut-off centrifugal filter
units (Millipore, Billerica MA, USA). The concentrated recombi-
nant proteins were loaded onto a HiTrap Protein G HP column
(GE Healthcare) and immobilized via Fc-protein G binding. The
column was washed with 20mM sodium phosphate buffer (pH 7.0)
and the recombinant protein was eluted using 0.1M glycine-Cl
buffer (pH 2.8). Protein concentrations were determined with the
Coomassie Plus protein assay (Pierce, Rockford, USA) and purity
was estimated by SDS polyacrylamide gel electrophoresis.
DNA Vaccination and Electroporation-mediated
Intramuscular Injection
DNA-coated gold particle-mediated DNA vaccination was
performed using a helium-driven gene gun (BioRad Laboratories,
Inc., Hercules, CA, USA) as described in [17]. CRT/E7-encoding
DNA-coated gold particles were delivered to the shaved
abdominal region of mice using a helium-driven gene gun
(BioRad Laboratories, Inc.) with a discharge pressure of 400 psi.
C57BL/6 mice were immunized with 2mg of the CRT/E7 plasmid
three times at 3-day intervals.
The pCon-Fc, pCon-Fc-GLuc, pNKG2D-Fc, pNKG2D-Fc-
GLuc, pCon-Fc-IL2, and pNKG2D-Fc-IL2 plasmids were
delivered intramuscularly by syringe needle injection. The specifics
of the procedure are similar to those found in [18,19]. In short,
hair around the quadriceps femoris muscle of mice was removed
and 40mg of plasmid DNA was injected. Immediately following the
injection two-needle array electrodes (BTX, San Diego, CA) were
inserted with a separation distance of 5 mm with the array inserted
longitudinally relative to the fibers. Electric pulses were generated
using a square-wave electroporator (Model 830; BTX). In vivo
electroporation parameters were as follows: distance between the
electrodes, 100 V/cm; pulse duration, 50 ms; 10 pulses with
reversal of polarity.
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For in vitro flow cytometry analysis, samples of 2x10
5 tumor
cells were incubated with 0.5mg purified recombinant protein or
anti-mouse Rae-1 antibody (BD Bioscience). PE-conjugated anti-
mouse Fc secondary antibody (BD Bioscience) was used as a
detection antibody. To confirm that the chimeric protein could
be generated and released in vivo, pCon-FC, pNKG2D-Fc, pCon-
Fc-IL2, or pNKG2D-Fc-IL2 plasmids were intramuscularly
injected followed by electroporation into naı ¨ve mice (3 mice/
group). After 2 days, blood sera from mice were collected and
diluted 1:50 for TC-1 cell staining. Again, PE-conjugated anti-
mouse Fc secondary antibody was used as a detection antibody
(BD Bioscience). CELLQuest software (Becton Dickinson Im-
munocytometry System, Mountain View, USA) was used for
FACScan analysis with methods similar to those previously
described [17].
Luciferase-based Bioluminescence Imaging
Gaussia luciferase (GLuc) [20] and the substrate coelenterazine
(Sigma) were used to test for GLuc activity in vitro and in vivo. For in
vitro cell staining, TC-1 cells were added to 24-well plates at 1610
5
cells/well and incubated overnight. The next day, 1mgo f
recombinant Con-Fc, Con-Fc-GLuc, NKG2D-Fc, or NKG2D-
Fc-GLuc protein was added into each well and incubated for 20
minutes at 37uC. The wells were washed twice with PBS before
coelenterazine was added. Bioluminescence of the cells was
detected via the IVIS Imaging System 200 Series. The region of
interest from displayed images was designated and quantified as
total photon counts using Living Image 2.50 software (Xenogen).
For the in vivo luciferase attraction experiment, mice were injected
with 1610
5 TC-1 cells. After 10 days, pCon-Fc-GLuc or
pNKG2D-Fc-GLuc plasmid was intramuscularly injected followed
by electroporation. The following day, coelenterazine was
intraperitoneally injected and the bioluminescence of the cells
was detected as described above. For the in vitro cell staining and
T-cell proliferation experiments, 5610
4 irradiated MOSEC cells
were added to 48-well plates and incubated overnight. The
following day, recombinant Con-Fc, NKG2D-Fc, Con-Fc-IL2, or
NKG2D-Fc-IL2 protein was added and incubated for 30 min in
37uC. After washing twice with PBS, 1610
5 luciferase-expressing
E7-specific CD8+ T cells was added to each well and allowed to
incubate for five days. The levels of light from the bioluminescent
cells were detected as described above. For the in vivo T cell
attraction experiment, mice were injected with 1610
5 TC-1 cells.
After ten days, 40mg pCon-Fc, pNKG2D-Fc, pCon-Fc-IL2, or
pNKG2D-Fc-IL2 plasmid was injected using intramuscular
injection followed by electroporation and 5x10
6 luciferase-
expressing E7-specific CD8+ T cells were adoptively transferred
intravenously through the tail vein into the mice. Five days after
injection, the bioluminescence of the cells was detected as
described above.
In Vivo Tumor Treatment Experiments
For the TC-1 tumor treatment experiment, naı ¨ve mice were
subcutaneously challenged with 16l0
5 TC-1 tumor cells/mouse.
After six days, the mice were vaccinated using the procedure
described above with pCRT/E7 via gene gun, followed by
plasmids of pCon-Fc, pNKG2D-Fc, pCon-Fc-IL2, or pNKG2D-
Fc-IL2 using electroporation-mediated intramuscular injection
three times at 3-day intervals starting 12 days after vaccination.
Tumor growth was monitored by palpation and inspection twice
a week until the mice died.
Statistical Analysis
Experiments were performed in duplicate or triplicate. The data
presented here are of one representative experiment, and are
expressed as means 6 standard deviation (S.D.). The number of
samples in each group for any given experiment was .5. Results
for intracellular cytokine staining with flow cytometry analysis and
tumor treatment experiments were evaluated by analysis of
variance (one-way ANOVA) and the Turkey-Kramer multiple
comparison test. Comparisons between individual data points
were performed using Student’s t-test. The event time distributions
for different mice were compared using the Kaplan-Meier method
and the log-rank statistic. All p values , 0.05 were considered
significant.
Results
The NKG2D-Fc Protein Binds to Tumor Cells Expressing
Murine NKG2D Ligands
We have successfully isolated the NKG2D-Fc and Con-Fc
proteins from the DNA-transfected BHK-21 cells and used SDS-
PAGE to assess their size and purity, as shown in Figure 1A. The
stained gel shows bands of high purity and of the expected size for
both proteins.
To determine if the purified NKG2D-Fc could bind to murine
NKG2D ligand-expressing tumor cells, we selected three NKG2D
ligand-expressingtumorcelllines(TC-1,MOSEC,andOVHM;all
express Rae-1, a murine NKG2D ligand) and one Rae-1-negative
tumor cell line (B16F10). As shown in Figure 1B, NKG2D-Fc
boundtoallthreeoftheNKG2Dligand-expressingtumorcelllines,
but not to the Rae-1-negative tumor cells. This is consistent with
previous reports that cells engineered to express the extracellular
domain of murine NKG2D are capable of recognizing and binding
tocellsNKG2Dligand-expressingcells,includingRae-1-expressing
cells[21].WefurtherdemonstratedthatNKG2D-FcboundtoRae-
1-expressing tumor cells through the NKG2D component, rather
than the Fc component, since Con-Fc (which does not have the
NKG2D component) failed to generate significant binding (see
Figure S2). Taken together, these data suggest NKG2D-Fc is
capable of binding NKG2D ligand-expressing tumor cells.
The Linkage of NKG2D-Fc to Gaussia Luciferase (GLuc)
Lends Confirmation that the Constructed Chimeric
Molecule Targets the Tumor Loci in Tumor-bearing Mice
In order to determine if NKG2D-Fc could serve as a reliable
strategy for directing the constructed protein to tumor cells,
particularly to the tumor loci in tumor-bearing mice, we used
Gaussia luciferase (GLuc) as a marker protein. We successfully
generated and isolated the chimeric NKG2D-Fc-GLuc protein as
well as the control protein, Con-Fc-GLuc. As shown in Figure 2A,
we used SDS-PAGE to assess the size and purity of the proteins.
The stained gel shows prominent bands of high purity and of the
expected size for NKG2D-Fc-GLuc, Con-Fc-GLuc, and NKG2D-
Fc.
To determine both the functionality of the Gaussia luciferase and
the binding specificity of the NKG2D-Fc-GLuc protein to Rae-1-
expressing tumorcells,we incubated NKG2D-Fc-Gluc withRae-1-
expressingTC-1tumorcells.Equivalentassayswerealsocompleted
with relevant control proteins. The treated tumor cells were washed
and incubated with the substrate coelenterazine before being
imaged with the IVIS Imaging System 200 Series. As shown in
Figures 2B and 2C, only the TC-1 tumor cells treated with
NKG2D-Fc-GLuc demonstrated significant luciferase activity,
when compared to TC-1 tumor cells incubated with the Con-Fc-
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suggest that the linkage of NKG2D-Fc to Gaussia luciferase does not
interfere with the specific binding of the chimeric protein to Rae-1-
expressing tumor cells, nor does the linkage affect the enzymatic
function of the Gaussia luciferase.
We then determined if tumor-bearing mice injected with the
DNA construct encoding the NKG2D-Fc-GLuc protein would be
able to target and concentrate the chimeric protein at the tumor
loci of the injected mice. TC-1 tumor-bearing mice were
intramuscularly injected with DNA encoding either the
NKG2D-Fc-GLuc or Con-Fc-GLuc protein, followed by electro-
poration. Administration of coelenterazine followed, and the mice
were imaged using the IVIS Imaging System 200 Series. As shown
in Figures 2D and 2E, tumor-bearing mice injected with the
NKG2D-Fc-GLuc DNA construct showed significant luminescent
activity concentrated at the tumor loci. In contrast, the tumor-
bearing mice injected with Con-Fc-GLuc DNA construct did not
demonstrate any luciferase activity. Collectively, our data show
that NKG2D-Fc linked to Gaussia luciferase can target and
concentrate the Gaussia luciferase at the tumor loci in tumor-
bearing mice. Thus, we have created a system to target the
constructed protein to the NKG2D ligand-expressing tumor in
vivo.
NKG2D-Fc-IL2 is Capable of Binding to NKG2D Ligand-
expressing Tumor Cells while Preserving IL-2
Functionality of Stimulating T Cell Proliferation
IL-2 has been shown to promote T cell proliferation. We
reason that the specific delivery of IL-2 to the tumor loci may
enhance the proliferation of tumor specific CD8+ T cells in the
tumor microenvironment. In order to determine if the NKG2D-
Fc protein could be used to deliver IL-2 to the tumor loci, we
linked NKG2D-Fc to IL-2, generating the chimeric NKG2D-Fc-
IL2 protein. We successfully generated and isolated the NKG2D-
Fc-IL2 protein from DNA-transfected BHK-21 cells and used
SDS-PAGE to assess the size and purity of the NKG2D-Fc-IL2
protein, as well as the relevant control proteins (NKG2D-Fc,
Con-Fc-IL2, and Con-Fc). As shown in Figure 3A, the stained
gel shows bands of high purity and of the expected size for all
proteins.
In order to determine if NKG2D-Fc-IL2 can bind to NKG2D
ligand-expressing tumor cells while preserving the IL-2 function-
ality of promoting T cell proliferation, we incubated NKG2D-Fc-
IL2 with irradiated MOSEC tumor cells, alongside equivalent
assays with relevant control proteins. The treated tumor cells were
washed and incubated with luciferase-expressing E7-specific T
cells for five days. The proliferation of T cells was measured by
bioluminescence imaging using the IVIS Imaging System 200
Series. As shown in Figures 3B and 3C, the MOSEC tumor
cells treated with NKG2D-Fc-IL2 demonstrated significantly
more luciferase activity in comparison to the MOSEC tumor
cells treated with Con-Fc-IL2, NKG2D-Fc, or Con-Fc, or to the
control (no treatment). These data suggest that the chimeric
NKG2D-Fc-IL2 protein is capable of binding to Rae-1-expressing
tumor cells and the IL-2 component is functionally capable of
promoting the proliferation of antigen-specific CD8+ T cells.
TC-1 Tumor-bearing Mice Injected with DNA Encoding
NKG2D-Fc-IL2 Exhibit an Increased Number of Luciferase-
expressing E7-specific CD8+ T Cells at the Tumor Site
In order to determine if (1) mice could be injected intramus-
cularly with the DNA construct encoding NKG2D-Fc-IL2 and
successfully produce detectable amounts of the chimeric protein
and (2) the protein was capable of targeting NKG2D ligand-
expressing tumor cells in vivo, TC-1 tumor-bearing mice were
intramuscularly injected with DNA constructs encoding NKG2D-
Fc-IL2, NKG2D-Fc, Con-Fc-IL2, Con-Fc, or no protein, followed
by electroporation. To test the production of chimeric protein,
serum samples were collected from each mouse following
treatment, incubated with TC-1 tumor cells in vitro, and prepared
for flow cytometry analysis. As shown in Figure 4A, the samples
containing NKG2D-Fc and NKG2D-Fc-IL2 produced shifts
significantly different from the TC-1 tumor cells treated with
Con-Fc or Con-Fc-IL2, demonstrating that intramuscular injec-
tion of a DNA construct encoding the proteins consisting of
Figure 1. Characterization of the murine NKG2D-Fc protein. (A) Gel electrophoresis was used to characterize the size of the purified NKG2D-
Fc and Con-Fc proteins. The NKG2D-Fc and Con-Fc proteins were purified from BHK-21 cells transfected with the pFuse-Fc and pFuse-NKG2D-Fc DNA
constructs. The purity and size of isolated protein was characterized by SDS-PAGE, followed by staining with Coomassie brilliant blue. The arrows
indicate the proteins of interest. (B) Characterization of the binding of NKG2D-Fc to Rae-1 expressed in different tumor cells using flow cytometry.
doi:10.1371/journal.pone.0035141.g001
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amounts of functional chimeric protein in the serum.
We further determined that the TC-1 tumor-bearing mice
treated with the DNA construct encoding NKG2D-Fc-IL2 could
exhibit enhanced proliferation of the luciferase-expressing E7-
specific CD8+ T cells at the tumor loci. After injection with the
DNA construct followed by electroporation, the TC-1 tumor-
bearing mice were injected with luciferase-expressing E7-specific
CD8+ T cells. After five days, bioluminescence imaging of the
mice was performed using the IVIS Imaging System 200 Series.
As shown in Figures 4B, the tumor-bearing mice injected with
NKG2D-Fc-IL2 showed significant luciferase activity at the
tumor loci. In contrast, the other treated mice showed no
significant luciferase activity. Taken together, our data show
that TC-1 tumor-bearing mice injected with the DNA construct
encoding NKG2D-Fc-IL2 are capable of delivering IL-2 to the
tumor loci, resulting in local proliferation and accumulation of
E7-specific CD8+ T cells.
Figure 2. Characterization and luminescence activity of NKG2D-Fc-GLuc protein. (A) Gel electrophoresis was used to characterize the size
of the purified NKG2D-Fc-GLuc, Con-Fc-GLuc, and NKG2D-Fc proteins. The purity and size of the isolated proteins were characterized by SDS-PAGE,
followed by staining with Coomassie brilliant blue. The arrows indicate the proteins of interest. (B) Representative figure of bioluminescent imaging
in TC-1 cells incubated with the different purified proteins. TC-1 cells were plated into a 24-well plate. The purified proteins (Con-Fc, NKG2D-Fc, Con-
Fc-GLuc, and NKG2D-Fc-GLuc) were added to the TC-1 tumor cells. The binding of NKG2D-Fc-GLuc to TC-1 cells was characterized by bioluminesence
imaging using the IVIS Imaging System 200 Series. (C) Histogram depicting the bioluminescence measured in Figure 2B. The p-value found was less
than 0.001. (D) Representative bioluminescence imaging to demonstrate the specific targeting of NKG2D-Fc-GLuc to TC-1 tumor cells in vivo. TC-1
tumor-bearing C57BL/6 mice were injected intramuscularly with the DNA constructs encoding the Con-Fc-GLuc or NKG2D-Fc-GLuc protein, followed
by electroporation. The treated mice were imaged for bioluminescence using the IVIS Imaging System 200 Series. (E) Histogram of the
bioluminescence imaging found in Figure 2D. Note: there is a significant difference in the bioluminescence of the tumors between the mice injected
with the DNA constructs for Con-Fc-Glu and NKG2D-Fc-Glu (P-value less than 0.001).
doi:10.1371/journal.pone.0035141.g002
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Significantly Enhanced the Therapeutic Anti-tumor
Effects Generated by Intradermal Vaccination with
Therapeutic HPV DNA in Tumor-bearing Mice
We have previously demonstrated that the intradermal admin-
istration of a DNA vaccine encoding Calreticulin linked to E7
(CRT/E7) via gene gun was able to generate high numbers of E7-
specificCD8+T-cellimmuneresponsesandtherapeuticanti-tumor
effects in vaccinated mice [22]. Therefore, in the current study we
determinediftheanti-tumoreffectsintumor-bearingmicereceiving
the CRT-E7 DNA vaccine could be enhanced by additional
treatment with the DNA construct encoding NKG2D-Fc-IL2. The
tumor-bearing mice were first treated with the CRT/E7 DNA
vaccineviagenegunandlaterreceivedanintramuscularinjectionof
the DNA construct encoding NKG2D-Fc-IL2 followed by electro-
poration (see Figure 5A for a schematic diagram of the procedure).
As shown in Figure 5B, the vaccinated tumor-bearing mice
receiving the NKG2D-Fc-IL2 construct demonstrated a significant
reduction in tumor mass growth, when compared to the other
groups of mice receiving NKG2D-Fc, Con-Fc-IL2, or Con-Fc, or
the DNA vaccine alone. Furthermore, as shown in Figure 5C, the
tumor-bearing mice receiving the NKG2D-Fc-IL2 construct
exhibited prolonged survival, in comparison the other tumor-
bearingmicetreatedwiththeotherDNAconstructs.Thus,ourdata
suggest the additional administration of the DNA construct
encoding NKG2D-Fc-IL2 is able to enhance the therapeutic anti-
tumor effect first generated by the gene gun-administered CRT-E7
DNA vaccine.
Discussion
In this study, we demonstrated that a constructed protein,
NKG2D-Fc, was able to bind to murine NKG2D ligand-
expressing tumor cells. Furthermore, we were able to use the
NKG2D-Fc protein to deliver both a marker protein (GLuc) and
IL-2 to the tumor loci in tumor-bearing mice. More importantly,
we demonstrated that IL-2 linked to NKG2D-Fc led to significant
proliferation of the tumor-specific CD8+ T-cell at the tumor loci
and resulted in potent therapeutic anti-tumor effects in TC-1
tumor-bearing mice that received the therapeutic HPV16/E7
DNA vaccine. Thus, our study demonstrated that constructed
proteins containing NKG2D are capable of specifically targeting
NKG2D ligands, often found to be overexpressed on tumor cells,
making the NKG2D-ligand system an exploitable receptor-ligand
system to bring potentially immune-modulating or therapeutic
molecules to the tumor site.
The success of this approach, using NKG2D ligands as specific
targets highly expressed in many tumor cells, warrants further
exploration of other molecules that are also uniquely expressed on
the surface of tumor cells, but not found on normal tissue. One
example is mesothelin – a protein also commonly overexpressed
on many human cancer cells, including ovarian [23,24] and
pancreatic cancer [24]. Other potential target molecules for
targeting ovarian cancer cells might include follicle-stimulating
hormone receptor (FSHR) [25], intercellular adhesion molecule 1
(ICAM-1) [26], Mu ¨llerian inhibiting substance type II receptor
(MISIIR) [27], or human epidermal growth factor receptor 2
(HER2) [28]. Prostate-specific membrane antigen (PSMA) is
Figure 3. Characterization of NKG2D-Fc-IL2 protein. (A) Gel electrophoresis was used to characterize the size of the purified NKG2D-Fc-IL2,
NKG2D-Fc, Con-Fc-IL2, and Con-Fc proteins. The purity and size of the isolated proteins were characterized by SDS-PAGE, followed by staining with
Coomassie brilliant blue. The arrows indicate the proteins of interest. (B) Representative figure of the T-cell proliferation assay using bioluminescent
imaging in irradiated MOSEC cells incubated with the different purified proteins. MOSEC cells were plated into a 24-well plate. The purified proteins
(Con-Fc, NKG2D-Fc, Con-Fc-IL2, and NKG2D-Fc-IL2) were added to the MOSEC tumor cells, allowed to incubate, and then washed. Luciferase-
expressing E7-specific T cells were added and incubated for five days. The proliferation of the T cells was characterized by bioluminescence imaging
using the IVIS Imaging System 200 Series. (C) Histogram of the luminescence imaging cubated NKG2D-Fc-IL2 than in the wells incubated with
NKG2D-Fc or Con-Fc-IL2 (P-value less than 0.001).
doi:10.1371/journal.pone.0035141.g003
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than normal cells [29], therefore making PSMA a potential target
molecule for treating prostate cancer. With contemporary
technologies including deep sequencing, gene and protein
microarrays, proteomics, and many others, we expect to see more
potential candidate targets emerge in the near future. If these
candidate targets are, in actuality, uniquely expressed in cancer
cells but not in normal tissues, these targets can potentially be used
to deliver specific molecules to the tumor loci using its counterpart
through a receptor-ligand system or an antibody-antigen system.
The NKG2D-Fc system also allows us to deliver other immune-
modulating or anti-cancer molecules (i.e., other than IL-2) to the
tumor loci with the added benefit of reduced toxicity because of its
specific targeting capabilities. One potential concern with the
delivery of IL-2 to the tumor loci is the expansion of regulatory T
(Treg) cells. However, with the current study, we have shown that
the specific delivery of IL-2 with the NKG2D-Fc system led to
both the expansion of tumor antigen-specific CD8+ T cells at the
tumor loci and an improved therapeutic anti-tumor effect
generated by the therapeutic DNA vaccine. Thus, our data
suggest the expansion of Treg cells by the local delivery of IL-2
does not significantly impede the therapeutic anti-tumor effect
generated by the therapeutic HPV DNA vaccine. Some other
potential candidates for anti-cancer molecules are molecules that
can activate immune responses in the tumor microenvironment,
such as GM-CSF (granulocyte macrophage colony-stimulating
factor) or IL-12. IL-15 has even been shown to be more effective
than IL-2 for tumor growth inhibition [5]. The use of these
molecules could relieve the concerns of Treg expansion.
Molecules capable of countering the immunosuppressive factors
Figure 4. Characterization of T cell accumulation in tumor-bearing mice intramuscularly injected with DNA constructs with
electroporation. (A) Characterization of the binding of NKG2D-Fc-containing protein to TC-1 tumor cell using serum from mice injected
intramuscularly with the various DNA constructs in conjunction with electroporation. Mice were intramuscularly injected with one of four DNA
constructs. Serum was collected from the mice and incubated with TC-1 tumor cells. The cells were incubated with anti-Fc-PE and characterized by
flow cytometry. Note: the tumor cells incubated with the serum from mice injected with the DNA constructs encoding NKG2D-Fc or NKG2D-Fc-IL2 led
to a significant shift compared to other constructs. (B) Representative bioluminescence imaging used to characterize the presence of luciferase-
expressing E7-specific CD8+ T cells in tumor-bearing mice injected intramuscularly with different DNA constructs followed by electroporation. TC-1
tumor bearing mice were injected intramuscularly with one of the four DNA constructs, followed by electroporation. Luciferase-expressing T cells
were injected intravenously into the lateral tail vein and the bioluminescence was imaged five days later. Note: the luciferase-expressing T cells
proliferated locally to the tumor site in the mice injected with DNA encoding NKG2D-Fc-IL2 but not in others. (C) Histogram of the bioluminescence
imaging depicted in Figure 4B. Note: the luminescence of the tumors between the mice injected with NKG2D-Fc-IL2 and those not (P-value less than
0.001).
doi:10.1371/journal.pone.0035141.g004
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tion, as are molecules capable of directly leading to tumor cell
death or growth inhibition, such as Pseudomonas exotoxin-A or
other bacterial toxins.
One potential limitation for the clinical translation of the
proposed approach is antibody generation, specifically against the
chimeric protein. If antibodies are generated to the chimeric
protein, subsequent challenges may be affected. Therefore, as a
step towards clinical translation, it will be important to use the
human counterparts for the murine IL-2, Fc, and NKG2D of this
study to generate a clinical grade reagent such that the immune
response against the chimeric protein will be limited. It will also be
important to test the binding ability of the human NKG2D-Fc-IL2
to different human cancer cell lines, as well as characterize the
functionality of the IL-2 component before considering the
generation of a clinical grade reagent for clinical trials.
In summary we have successfully developed a strategy to
specifically target anti-cancer molecules to tumor loci. Such a
strategy can potentially be used to deliver various anti-cancer
molecules to the tumor loci for therapeutic anti-tumor effects.
Since NKG2D ligands are highly expressed in many different
tumor cells, our strategy represents a potentially useful approach
for delivering molecules of interest to the tumor loci for the control
of different kinds of tumors for future clinical translation.
Supporting Information
Figure S1 Structure of the various chimeric genes.
Schematic diagram to illustrate the composition of the various
chimeric genes used in DNA constructs
(TIF)
Figure S2 NKG2D-Fc binds to Rae-1 expressing tumor
cells through the NKG2D component. Flow cytometry to
characterize the binding of NKG2D-Fc and Con-Fc to tumor
cells. TC-1 and MOSEC cell lines were incubated with either
purified Con-Fc or NKG2D-Fc proteins followed by a stain using
secondary phycoerythrin-labeled (PE) antibody against Fc (anti-Fc-
PE). Note that the larger shifts for NKG2D-Fc show that
NKG2D-Fc can bind to both the TC-1 and MOSEC cell lines.
On the other hand, Con-Fc generates only a minor shift in
comparison to the control.
(TIF)
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Figure 5. Therapeutic anti-tumor effects of intramuscular injection of different DNA constructs in vaccinated tumor-bearing mice.
(A) Schematic diagram depicting the regimen. On Day 1, TC-1 cells were injected subcutaneously. Five days later, the mice were vaccinated with the
CRT/E7 DNA vaccine via gene gun, with boosters of the same dose given on Days 9 and 12. On Days 12, 15, and 18, the mice were intramuscularly
injected with one of the DNA constructs, followed by electroporation. (B) Line graph illustrating the changes in tumor size in the TC-1 tumor-bearing
mice over time. The dimensions of the tumor were characterized by measurement. (C) Kaplan-Meier survival analysis of the tumor-bearing mice
following the TC-1 tumor challenge and treatment.
doi:10.1371/journal.pone.0035141.g005
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